These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 20072836)

  • 21. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A
    Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical development of decitabine as a prototype for an epigenetic drug program.
    Rosenfeld CS
    Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review: recent clinical trials in epigenetic therapy.
    Oki Y; Issa JP
    Rev Recent Clin Trials; 2006 May; 1(2):169-82. PubMed ID: 18473969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
    Momparler RL; Côté S; Eliopoulos N
    Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
    Issa JP
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decitabine. MGI Pharma Inc/SuperGen Inc.
    Arthur C
    IDrugs; 2004 Dec; 7(12):1113-32. PubMed ID: 15599805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
    Wijermans P; Lübert M
    Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decitabine is an effective treatment of idiopathic myelofibrosis.
    Danilov AV; Relias V; Feeney DM; Miller KB
    Br J Haematol; 2009 Apr; 145(1):131-2. PubMed ID: 19133981
    [No Abstract]   [Full Text] [Related]  

  • 35. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
    Drugs R D; 2003; 4(3):179-84. PubMed ID: 12757405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
    Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
    Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of hypomethylating agents in myelodysplastic syndromes.
    Atallah E; Garcia-Manero G
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting DNA methylation.
    Issa JP; Kantarjian HM
    Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
    Tohyama K
    Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
    Claus R; Almstedt M; Lübbert M
    Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.